ClinicalTrials.gg
RecruitingNCT05706454Updated Jan 31, 2023

Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia

A Phase 2/3 interventional study of Ramatroban and Placebo in COVID-19 Pneumonia and COVID-19 Respiratory Infection, sponsored by KARE Biosciences. Recruiting at 7 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by KARE Biosciences · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in COVID-19 with a site in India — 7 open to participants now, 9 under way, 4 of them phase 3. COVID-19 · India.

Planned enrollment
34th of 75
324 · median 272
Started
2022
with 17 others
Phase 2/3
8 of 113
1 open now
Registered
111th of 113
by date

Among the 113 studies in COVID-19 with a site in India, this one is the 34th largest by planned enrollment of the 75 interventional ones that give a count, is one of 18 that started in 2022, is one of 8 in phase 2/3, and was the 111th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

7 of the 113 studies in COVID-19 with a site in India are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in COVID-19 with a site in India, or all of them as a file.
02

Study summary

Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.

Approximately 324 eligible subjects will be randomized in a 1:1 ratio to one of the two treatment groups.

Group I: Ramatroban 75 mg tablet + Standard of care; Group II: Placebo + Standard of care.

Phase 2

Primary Objective:

To evaluate the safety of Ramatroban 75 mg tablet with the standard of care against Placebo with the standard of care in COVID-19 hospitalized subjects.

Secondary Objective:

To assess the efficacy of Ramatroban 75 mg tablet with the standard of care against Placebo with the standard of care in COVID-19 hospitalized subjects.

Phase 3

Primary Objective:

To evaluate the efficacy of Ramatroban 75 mg tablet with the standard of care against Placebo with the standard of care in COVID-19 hospitalized subjects.

Secondary Objective:

To evaluate the safety of Ramatroban 75 mg tablet with the standard of care against Placebo with the standard of care in COVID-19 hospitalized subjects.

Long COVID [Follow-up Phase- Objectives- (Phase 2 \& 3)]

  1. To examine lipid mediators, specifically thromboxane A2, prostaglandin D2, F2-isoprostane and/or their metabolites in convalescent subjects after treatment.
  2. To assess the efficacy of Ramatroban administered during the acute illness in preventing/mitigating subsequent development of long COVID / PASC
03

Conditions studied

  • COVID-19 Pneumonia
  • COVID-19 Respiratory Infection

Browse trials for

Keywords

  • COVID-19
  • Ramatroban
  • Post-Acute Sequelae SARS-CoV-2 infection (PASC)
  • Thromboxane
  • Prostaglandin D2
  • F2-Isoprostane
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects of age 18 years and above.
  2. Subject (or legally authorized representative) willing to provide and agrees to comply with planned study procedures.
  3. Subjects hospitalized for SARS-COV-2 infection, having hypoxemia (SpO2: ≤ 93% on room air) and radiological evidence supporting COVID-19 pneumonia.
  4. Subjects meeting 8-point WHO Ordinal Scale 5 or 6
  5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay in any specimen, as documented by either of the following:

    1. PCR positive in a sample collected \< 72 hours prior to randomization; OR
    2. PCR positive in sample collected ≥ 72 hours but \< 10 days prior to randomization AND non-improving or progressive disease suggestive of ongoing SARS-CoV-2 infection.

    i. Note: In case if the subject is not having previous reports, a quantitative analysis will be performed

  6. Women of must agree to either abstinence or use at least one primary form of not including hormonal contraception from the time of screening through Day 36.
  7. Agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of COVID-19 through-out the study period

Exclusion criteria

Exclusion Criteria:

  1. Subject with immediately life-threatening SARS-CoV-2 infection.

    -Life-threatening disease is defined as respiratory failure, septic shock, and/or multiple organ dysfunction or failure

  2. Subjects on invasive mechanical ventilation at screening or randomization.
  3. Female subject who is pregnant, breastfeeding, or planning to become pregnant.
  4. Subject having other gastrointestinal (GI) disease/ GI surgery that in the opinion of the investigator would interfere with the absorption of Ramatroban or subject is unable to swallow oral medications.
  5. Subject with pre-existing clinically significant spontaneous bleeding abnormality, or any other condition as per investigator's judgment.
  6. Known / or infection.
  7. Severe liver disease (, AST >5 times the , total > 2 times the upper limit of normal).
  8. Subject with known severe renal impairment (estimated ≤30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis.
  9. Subject participated in any other clinical study using any drug in the past 30 days before the screening visit.
  10. Subject with a history of life-threatening neoplasms within 5 years prior to the screening visit, other than carcinoma in situ of the cervix or basal cell carcinoma of the skin.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
324 participants (estimated)

Study arms

  • Experimental
    Ramatroban 75 mg tablet

    Drug: Ramatroban

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugRamatroban

    Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days. Subjects will be evaluated over a study period of approximately 365 days.

    Also known as: BAYu3405, IUPAC Name: 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid

  • DrugPlacebo

    Matching placebo will be administered orally twice a day

06

What researchers measure

Primary outcomes

  1. Rate of Serious Adverse Events (SAE)

    Time frame: Baseline - Day 29

  2. Time to Clinical recovery (TTCR)

    Time frame: Baseline - Day 15

Secondary outcomes

  1. Composite endpoint of death or need for mechanical ventilation or ECMO

    Time frame: Baseline - Day 29

  2. Rate of mechanical ventilation or vasopressor therapy, or ECMO

    Time frame: Day 29

  3. Ventilator free days

    Time frame: Baseline-Day 29

  4. Duration of hospitalization

    Time frame: Baseline-Day 29

  5. Duration of ICU stay

    Time frame: Baseline-Day 29

  6. Number of subjects who had thrombotic events

    Time frame: Within Day 29

  7. Mortality rate

    Time frame: Till Day 29

  8. Change in hemoglobin, platelets, WBC, creatinine, need for renal replacement.

    Time frame: Baseline- Day 29

  9. Occurrence of serious ventricular arrhythmia

    Time frame: censored at hospital discharge

  10. Total red blood cell units transfused

    Time frame: Baseline -Day 29

  11. Major or Clinically Significant Non-Major Bleeding

    Time frame: Baseline -Day 29

  12. Change from baseline of inflammation and coagulation markers

    Time frame: Baseline- Day 29

07

Study locations

7 of 7 sites recruiting
  • DEC Health Care
    Nellore, Andhra Pradesh 524001, India
    Recruiting
  • Shakti Superspecialty Hospital
    Ahmedabad, Gujarat 382405, India
    Recruiting
  • Lifecare Hospital
    Mumbai, Maharashtra 400028,, India
    Recruiting
  • Sangvi Multispecialty Hospital Pvt Ltd
    Pune, Maharashtra 411027, India
    Recruiting
  • Saikrupa Hospital
    Pune, Maharashtra 411033, India
    Recruiting
  • Spandan Hospital
    Pune, Maharashtra 411033, India
    Recruiting
  • PDEA'S Ayurved Rugnalaya & Sterling Multispeciality Hospital
    Pune, Maharashtra 411044, India
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jul 2024, 19 months after the start.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 19 months is above that.

Counting every sponsor, half of 169 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Jan 31, 2023
StartActual
Nov 10, 2022
Primary completionEst.
Jul 1, 2024
CompletionEst.
May 31, 2026
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05706454
Lead sponsor
KARE Biosciences
Collaborators
JSS Medical Research Inc., Biomedical Advanced Research and Development Authority, Open Philanthropy, Charak Laboratories India Pvt. Ltd, Charak Foundation, BioLink Life Sciences, Inc.
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Nov 10, 2022
Primary completion
Jul 1, 2024 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Jan 31, 2023

Study contacts

Jayashri Krishnan, PhD
Contact
Jayashri.krishnan@jssresearch.com
9771407484
Sonika Newar, PhD
Contact
Sonika.newar@jssresearch.com
8800799887
Ajay Gupta, MD
principal investigator · KARE Biosciences
Martin Ogletree, PhD
study director · Points & Assists, LLC.
Deanna J Nelson, PhD
study director · BioLink Life Sciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion